Aurisco Pharmaceutical Co., Ltd

Aurisco has received its second marketing authorization approval in China for AOSHUTONG, the oral finished dosage form of Complex Packing Estradiol Tablets/Estradiol and Dydrogesterone Tablets, from China’s Health Authority, the NMPA. The launch of AOSHUTONG will provide Chinese women in perimenopause with a high-quality, long-term treatment option, meeting the demand for safer and more effective therapeutic solutions.